Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Operating Expenses (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Operating Expenses data on record, last reported at $5.9 million in Q3 2025.

  • For Q3 2025, Operating Expenses fell 17.24% year-over-year to $5.9 million; the TTM value through Sep 2025 reached $24.2 million, down 16.27%, while the annual FY2024 figure was $26.6 million, 10.09% down from the prior year.
  • Operating Expenses reached $5.9 million in Q3 2025 per MBRX's latest filing, up from $5.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $9.1 million in Q3 2022 and bottomed at $5.2 million in Q4 2021.
  • Average Operating Expenses over 5 years is $6.7 million, with a median of $6.4 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: surged 48.96% in 2021, then crashed 34.54% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $5.2 million in 2021, then soared by 35.38% to $7.0 million in 2022, then increased by 26.55% to $8.9 million in 2023, then dropped by 25.52% to $6.6 million in 2024, then fell by 11.09% to $5.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $5.9 million in Q3 2025, $5.7 million in Q2 2025, and $5.9 million in Q1 2025.